REHOVOT, Israel, September 22, 2016 /PRNewswire/ --
Yissum Research Development Company of the Hebrew University of Jerusalem, the technology-transfer company of the Hebrew University, announced today that Agrinnovation, an investment fund focused on agricultural inventions, has entered into an agreement for an investment in Cannabi-Tech Ltd., a medical cannabis company established in 2015, and based on research preformed in the laboratory of Prof. Oded Shoseyov from The Hebrew University's Robert H. Smith Faculty of Agriculture, Food and Environment.
Cannabi-Tech is developing the world's first accurate, affordable and easy-to-use device, for the non-destructive detection, analysis and automated sorting of individual medical cannabis flowers. The Company's proprietary technology combines Near Infra-Red (NIR) spectrometry and imaging tools to provide a sensitive method to detect and quantify the active compounds of the cannabis plant and a unique spectral fingerprint for each flower. The addition of a sorter will enable automated sorting of cannabis flowers by pre-set criteria suitable for mass production. An optional attachable label generator and automated packaging unit will pack flowers individually ensuring full composition and potency traceability and tracking for each and every flower from farmer to patient.
Currently inadequate testing protocols depend on sampling (statistics) for estimating the composition and potency of an entire batch of cannabis flowers based on the average of the results obtained from a selection of samples. Results are unreliable due to the heterogeneous nature of the cannabis plant. This creates a substantial risk for patients in need of exact composition and dosage for effective care. At present, no means are available to accurately examine cannabis flowers without destroying them in the process. This shortcoming reduces flower efficacy and commercial value.
Prof. Oded Shoseyov, Co-Founder and Chief Scientific Officer, Cannabi-Tech, said, "Cannabis composition and potency varies drastically between different flowers from the same plant and across different plants within the same strain. As a result, the only way to guarantee cannabis composition and potency is to test each and every flower independently. Furthermore, the benefit of herbal cannabis lies in the synergistic effect of its compounds. The medical cannabis opportunity cannot materialize in full until doctors do not have 100% confidence that each time they prescribe medical cannabis, it comes in a controlled and standardized condition, with the precise composition of active ingredients matching their patient's therapeutic needs."
Dr. Guy Setton, Co-Founder and CEO, Cannabi-Tech, stated, "We are excited to partner with Agrinnovation, which enables us to leverage the resources and capabilities of Yissum, a longtime leader the field of technology transfer with a successful track-record of commercializing early stage scientific research. Cannabi-Tech will use the proceeds to fund its R&D activities and initial business development efforts. In addition, we are in the midst of a financing round and are seeking additional funding."
"Cannabi-Tech's breakthrough technology is another example of the kind of innovative applied technologies originating from The Hebrew University's Faculty of Agriculture which includes over 100 researchers working on novel inventions in diverse fields such as agriculture, food, nutrition, veterinary medicine and clean-tech," added Dr. Ido Schechter, General Manager, Agrinnovation. "As the medical cannabis industry expands worldwide, there will be a significant rise in regulatory oversight, increased quality assurance and quality control testing, while growing market demand will need to be fulfilled by mass production, all which will drive Cannabi-Tech's growth."
About Medical Cannabis
Medical cannabis is provided to patients for relief from disease symptoms and pain, as well as physical and mental stress. The international medical cannabis market is forecasted to be worth approximately $20 billion within a decade. About 1% of the global population are potential medical cannabis users during their lifetime. Growth will be driven by increasing public support and endorsement by the medical community, better understanding of the plant's healthy attributes, the roll-out of high quality and standardized products, and new markets coming online.
Founded in 2015, Agrinnovation is an investment fund focused on agricultural inventions originating from The Hebrew University's Robert H. Smith Faculty of Agriculture, Food and Environment. Its portfolio currently includes four technologies: protective coating for extension of shelf-life of fruits and vegetables; injectable controlled release platform for single-dose veterinary therapy; a new approach for electronic pest and insect control; and non-destructive detection, analysis and sorting of medical cannabis flowers. Investors include Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., UBS Agri Ventures Pty Ltd., Provident Fund of The Hebrew University of Jerusalem Ltd. and Kingenta Livnat Agri-science Development, Limited Partnership.
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. was founded in 1964 to protect and commercialize the Hebrew University's intellectual property. Products based on Hebrew University technologies that have been commercialized by Yissum currently generate $2 Billion in annual sales. Ranked among the top technology transfer companies in the world, Yissum has registered over 9,325 patents covering 2,600 inventions; has licensed out 880 technologies and has spun out 110 companies including Mobileye, Briefcam, Orcam, Avraham Pharmaceuticals, Betalin Therapeutics, CollPlant and Qlight Nanotech. Yissum's business partners span the globe and include companies such as Microsoft, Intel, Johnson & Johnson, Novartis, Roche, Merck, Teva, Syngenta, Monsanto and many more. For further information please visit http://www.yissum.co.il.
Global Media Liaison, Yissum Ltd.
Last updated on: 23/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.